When combined with your IBS subtype, symptom history, and current medications, this genetic information can support a more nuanced conversation about dosing strategy, monitoring expectations, and risk mitigation
But worth looking into the program if GLP-1 medications have been prescribed or discussed with their doctors
But for most, he says, there's an element of negative reinforcement
These occurred more frequently than with placebo, but less frequently than with liraglutide [39]
Key results from Calocurbs fourth human clinical study include the following: Calocurb is clinically shown to improve body composition by reducing body fat without losing muscle mass Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group Over 6.5x greater reduction in body fat vs placebo Average body fat loss of 9.9 lbs (4.49 kg) vs 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb vs placebo 3.5x greater reduction in visceral fat vs placebo Average visceral fat loss of 5 in 2 (32.5 cm2) vs 1.4 in 2 (9.1 cm2) lost after six months of consistent use of Calocurb vs placebo For over a decade, Calocurb has undertaken ground-breaking clinical research into Amarasate to continue bringing natural weight management solutions to those interested in GLP-1 and weight loss options

With physician oversight and individualized treatment planning, medical weight loss becomes a reliable pathway to meaningful, lasting improvement for patients at any stage of their weight loss journey